7.275
전일 마감가:
$7.495
열려 있는:
$7.48
하루 거래량:
1.32M
Relative Volume:
0.51
시가총액:
$808.86M
수익:
$24.30M
순이익/손실:
$-145.57M
주가수익비율:
-5.4699
EPS:
-1.33
순현금흐름:
$-149.17M
1주 성능:
-20.71%
1개월 성능:
-14.95%
6개월 성능:
+396.92%
1년 성능:
+22.34%
Tango Therapeutics Inc Stock (TNGX) Company Profile
명칭
Tango Therapeutics Inc
전화
(857) 320-4900
주소
201 BROOKLINE AVENUE, BOSTON
TNGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
TNGX
Tango Therapeutics Inc
|
7.27 | 1.00B | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.77 | 108.04B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
476.77 | 60.75B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
582.75 | 61.26B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
825.44 | 50.32B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
316.55 | 34.14B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-17 | 개시 | Jefferies | Buy |
| 2024-04-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 개시 | Piper Sandler | Overweight |
| 2023-12-08 | 개시 | B. Riley Securities | Buy |
| 2022-10-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 개시 | SVB Leerink | Outperform |
모두보기
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
Tango Therapeutics stock gains as Cantor Fitzgerald reiterates Overweight rating - Investing.com
How to build a dashboard for Tango Therapeutics Inc. stockJuly 2025 Selloffs & Low Drawdown Investment Strategies - newser.com
Is Tango Therapeutics Inc. stock entering bullish territoryChart Signals & High Conviction Buy Zone Picks - newser.com
Tango Therapeutics Inc. stock trend outlook and recovery pathWeekly Profit Analysis & Trade Opportunity Analysis Reports - newser.com
Ranking Tango Therapeutics Inc. among high performing stocks via toolsJuly 2025 News Drivers & Entry and Exit Point Strategies - newser.com
Why Tango Therapeutics Inc. stock is trending among retail tradersMarket Sentiment Summary & Technical Entry and Exit Tips - newser.com
Using AI based signals to follow Tango Therapeutics Inc.2025 Market Outlook & Proven Capital Preservation Tips - newser.com
Multi asset correlation models including Tango Therapeutics Inc.2025 Investor Takeaways & Reliable Volume Spike Alerts - newser.com
Tango Therapeutics Inc. (TNGX) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Guggenheim Maintains Tango Therapeutics (TNGX) Buy Recommendation - Nasdaq
Guggenheim Maintains Buy Rating and Raises Price Target for TNGX - GuruFocus
What analysts say about Tango Therapeutics Inc stockHigh Yield Income Stocks & Low Risk Trading Plans - earlytimes.in
Guggenheim raises Tango Therapeutics stock price target on promising cancer drug data - Investing.com
Tango Therapeutics price target raised to $12 from $10 at Guggenheim - TipRanks
Tango Therapeutics announces $225 million financing - The Pharma Letter
Form 424B5 Tango Therapeutics, Inc. - StreetInsider
Tango Therapeutics prices $210 million stock offering By Investing.com - Investing.com Nigeria
Tango Therapeutics Inc (TNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tango Therapeutics Inc 주식 (TNGX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Third Rock Ventures IV, L.P. | 10% Owner |
Sep 25 '25 |
Sale |
8.02 |
500,000 |
4,008,500 |
13,863,975 |
자본화:
|
볼륨(24시간):